AN ACT relating to coverage for prescription drugs.
Summary
SB211 would require certain Kentucky health plans to give immediate, favorable formulary placement to lower-cost generic drugs and biosimilars when they first enter the market. If a generic drug or biosimilar is marketed at a wholesale acquisition cost below the brand-name or reference product it replaces, the plan must make at least one such lower-cost option available on the formulary with better cost-sharing than the brand drug, and it may not impose prior authorization, step therapy, or similar utilization controls that make access harder than for the reference product. The bill also limits these protections to the period when the generic or biosimilar remains lower-cost, and it preserves a plan’s ability to remove coverage if clinical experts determine the drug is no longer medically appropriate or cost effective.
Impact
The bill amends Kentucky insurance law in KRS Chapter 304 to add a new prescription-drug coverage requirement that applies to health plans, including limited health service benefit plans, certain state postsecondary institution self-insured plans, and public employee health plans. It would affect how insurers and public plans design formularies, cost-sharing, and utilization management for generic drugs and biosimilars, and it expressly applies to plans issued or renewed on or after January 1, 2027. The bill also cross-references existing statutes governing public employee and postsecondary employee health coverage so that the new drug-coverage rule becomes part of those benefit structures.
Sentiment
No committee transcript or recorded vote information was provided, so the bill’s sentiment must be inferred from its text and status alone. The measure appears policy-driven and consumer-oriented, with a clear emphasis on lowering prescription-drug costs and improving access to generics and biosimilars. Its introduction and referral to Committee on Committees suggest it was still in the early legislative process at the time of the provided record.
Contention
The main point of contention is likely to be the balance between lower patient costs and insurer/pharmacy benefit manager flexibility. The bill restricts prior authorization, step therapy, and pharmacy access barriers for qualifying generics and biosimilars, which could draw concern from health plans that want to manage utilization and negotiate formulary placement. At the same time, the bill preserves some discretion for pharmacy and therapeutics committees to remove coverage if a drug is no longer medically appropriate or cost effective, indicating an attempt to limit but not eliminate clinical and cost-management authority.